TABLE 3

Positivity rate of MAC-ELISA using wt-VLP and FP-VLP from ZIKV and DENV-2/3 among four different groups of serum panels

Serum panel (no. of serum samples)No. positive/total no. tested (% positive)a
ZIKV-wt-VLPZIKV-FP-VLPDENV2/3-wt-VLPbDENV2/3-FP-VLP
ZIKV (21)21/21 (100)21/21 (100)20/21 (95.2)20/21 (95.2)
    Acute (23)16/23 (69.6)18/23 (78.3)22/23 (95.7)22/23 (95.7)
    Convalescent (19)18/19 (94.7)19/19 (100)19/19 (100)18/19 (94.7)
WNV (56)2/56 (3.6)0/56 (0)NANA
DENV (44)28/44 (63.6)*17/44 (38.6)*42/44 (95.5)38/44 (86.4)
    Acute (40)17/40 (42.5)*13/40 (32.5)*22/40 (55.0)15/40 (37.5)
    Convalescent (42)23/42 (54.8)*9/42 (21.4)*40/42 (95.2)38/42 (90.5)
Other (76)c0/76 (0)0/76 (0)0/76 (0)0/76 (0)
  • a *, P < 0.05, with statistical significance.

  • b The cutoff for DENV-2/3 VLP is based on our previous publications (13, 37).

  • c This was a control serum panel, including 10 yellow fever IgG-positive specimens (17D vaccinated), two St. Louis encephalitis virus (SLEV) IgM-positive specimens, 10 chikungunya virus IgM-positive specimens, 8 nonarboviral patients, and 46 normal human serum specimens from the CDC blood bank collection.